Form 4: P&G Health Care CEO Reports Stock Transactions
Insider Transaction Report
Jennifer L. Davis, CEO of Health Care at Procter & Gamble, reported the acquisition and disposition of common stock and restricted stock units.
Summary
- Jennifer L. Davis, CEO Health Care, reported transactions in Procter & Gamble Co (PG) common stock and Restricted Stock Units (RSUs).
- On December 3, 2025, Davis acquired 60.43 shares of common stock upon the exercise of a derivative security at a price of $144.35 per share.
- Concurrently, 60.43 shares of common stock were disposed of to cover tax obligations related to a previous Restricted Stock Unit grant, also at $144.35 per share.
- Davis also acquired 33.9576 Restricted Stock Units (RSUs) on November 17, 2025, as dividend equivalents.
- An additional 60.43 Restricted Stock Units were acquired on December 3, 2025, as a retirement award.
- Following these transactions, Davis directly beneficially owns 61,768.0786 shares of common stock and indirectly owns 15,535.3029 shares through a retirement plan trustee.
- Direct beneficial ownership of RSUs stands at 262.6603 (dividend equivalents) and 965.57 (retirement award).
Sentiment
Score: 5
Explanation: The filing reports routine insider transactions (exercise and tax withholding) which are generally neutral in sentiment. There are no indications of significant open market buying or selling that would suggest a strong positive or negative outlook from the insider.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The transactions represent a routine change in an executive's beneficial ownership, with no immediate material impact on the company's operations or strategic direction.
Key Dates
| Date | Description |
|---|---|
| 11/17/2025 | Acquisition of Restricted Stock Units (dividend equivalents). |
| 12/03/2025 | Acquisition of common stock upon exercise of derivative security, disposition of common stock for tax withholding, and acquisition of Restricted Stock Units (retirement award). |
| 12/05/2025 | Date of filing. |
Recommendation
holdThe Form 4 filing details routine insider transactions, specifically the exercise of derivative securities and subsequent tax-related dispositions, by a key executive. These types of transactions are common and often pre-scheduled under Rule 10b5-1 plans, indicating no new material information regarding the company's performance or outlook. Therefore, based solely on this filing, there is no basis to change an existing investment thesis, leading to a 'hold' recommendation.
Keywords
Procter & Gamble, PG, Jennifer L. Davis, Insider Trading, Form 4, Common Stock, Restricted Stock Units, CEO Health Care, Stock Transactions, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.